PLAN-AF: Endocardial Mapping of Left Atrium for Evaluation of Concomitant Surgical Ablation Lesions

Sponsor
University Medical Centre Ljubljana (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05714800
Collaborator
(none)
50
28

Study Details

Study Description

Brief Summary

Concomitant ablation is an effective treatment for patients with various types of atrial fibrillation undergoing heart surgery.

However, recurrences of tachycardias after concomitant ablation can happen and seem to be mostly related to reentry mechanism resulting in atrial tachycardias.

The aim of the study is to perform invasive re-mapping of ablated regions in the atria to assess durability of ablation lesions and prevalence of conduction gaps that can be targets for additional ablation to lower longterm arrhythmia recurrence.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Patients after concomitant ablation for treatment of atrial fibrillation will be enrolled. At ablation procedure pulmonary veins will be isolated and additional ablation lines will be performed in the left atrium (posterior wall box lesion, connecting lesion to the mitral annulus, connecting lesion to the left atrial appendage,...) and the right atrium (intercaval connecting lesion, cavotricuspid isthmus lesion,...) and left atrial appendage will be excluded (suture and excision, clipping device,...) at the discretion and expertise of the operator. Radiofrequency and/or cryoablation will be used at the discretion and expertise of the operator.

    Invasive mapping with a high density mapping catheter connected to a three-dimensional electro-anatomical mapping system will be performed to assess pulmonary vein isolation and linear lesion durability 3 months after the initial concomitant ablation. Potential gaps will be identified and ablated with a radiofrequency ablation catheter.

    Participants will be followed-up clinically and with holter ECG before and after the invasive re-mapping procedure up to the first year after the concomitant ablation procedure.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Endocardial Mapping of Left Atrium for Evaluation of Concomitant Surgical Ablation Lesions for Treatment of Atrial Fibrillation
    Anticipated Study Start Date :
    Feb 3, 2023
    Anticipated Primary Completion Date :
    Jun 3, 2024
    Anticipated Study Completion Date :
    Jun 3, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Prevalence of conduction gaps [3 months]

      Prevalence of conduction gaps in pulmonary vein isolation lines and linear ablation lines found at the invasive re-mapping procedure

    2. Prevalence of atrial fibrillation/tachycardia before and after delayed invasive re-mapping [12 months]

      ECG and holter ECG will be performed before and after the re-mapping procedure to assess possible change in prevalence related to closure of potential conduction gaps at the re-mapping procedure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • all patients scheduled for any kind of elective heart surgery having also indication (EHRA and/or HRS guidelines) to undergo concomitant ablation for any type of atrial fibrillation
    Exclusion Criteria:
    • life expectancy of less than one year,

    • severe heart failure with left ventricular ejection fraction below 35%,

    • emergency surgery due to a life threatening condition such as acute aortic dissection, papillary muscle rupture, acute endocarditis, major trauma,...

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University Medical Centre Ljubljana

    Investigators

    • Study Chair: Matevž Jan, MD, University Medical Centre Ljubljana

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Matevz Jan, Electrophysiology specialist, University Medical Centre Ljubljana
    ClinicalTrials.gov Identifier:
    NCT05714800
    Other Study ID Numbers:
    • PLAN-AF
    First Posted:
    Feb 6, 2023
    Last Update Posted:
    Feb 8, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Matevz Jan, Electrophysiology specialist, University Medical Centre Ljubljana
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 8, 2023